Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang luzetutazumab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The drug is intended for treatment with bevacizumab in patients with locally advanced EGFR mutations or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously failed to be treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang luzetutazumab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The drug is intended for treatment with bevacizumab in patients with locally advanced EGFR mutations or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously failed to be treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).